The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood

Luba Lopatinskaya; Anette H H van Boxel-Dezaire; Frederik Barkhof; Chris H Polman; Cornelis J Lucas; Lex Nagelkerken

doi:10.1016/s0165-5728(03)00089-4

The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood

J Neuroimmunol. 2003 May;138(1-2):123-31. doi: 10.1016/s0165-5728(03)00089-4.

Authors

Luba Lopatinskaya¹, Anette H H van Boxel-Dezaire, Frederik Barkhof, Chris H Polman, Cornelis J Lucas, Lex Nagelkerken

Affiliation

¹ Division of Immunological and Infectious Diseases, TNO Prevention and Health, P.O. Box 2215, 2301 CE, Leiden, The Netherlands.

PMID: 12742662
DOI: 10.1016/s0165-5728(03)00089-4

Abstract

In this longitudinal study, we examined the expression of Fas, FasL, CCR3, CCR5 and CXCR3 mRNA in peripheral blood mononuclear cells (PBMCs) of secondary progressive (SP) and relapsing-remitting (RR) multiple sclerosis (MS) patients. In RR patients, FasL, CCR3 and CCR5 mRNA levels were increased prior to the exacerbations, but these decreased during clinical activity, while mRNA levels of Fas increased. SP patients have increased the levels of Fas and FasL mRNA; the latter was particularly increased during lesional activity. Our data support the hypothesis that changes in Fas and FasL mRNA related to clinical activity are due to the migration of inflammatory cells to the central nervous system (CNS).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Apoptosis / immunology
CCR5 Receptor Antagonists
Cross-Sectional Studies
Down-Regulation / genetics
Down-Regulation / immunology*
Fas Ligand Protein
Humans
Ligands
Longitudinal Studies
Membrane Glycoproteins / antagonists & inhibitors*
Membrane Glycoproteins / biosynthesis
Membrane Glycoproteins / genetics
Middle Aged
Multiple Sclerosis, Chronic Progressive / blood
Multiple Sclerosis, Chronic Progressive / immunology
Multiple Sclerosis, Chronic Progressive / pathology
Multiple Sclerosis, Relapsing-Remitting / blood
Multiple Sclerosis, Relapsing-Remitting / immunology*
Multiple Sclerosis, Relapsing-Remitting / pathology
RNA, Messenger / antagonists & inhibitors*
RNA, Messenger / biosynthesis*
Receptors, CCR3
Receptors, CCR5 / genetics
Receptors, CXCR3
Receptors, Chemokine / antagonists & inhibitors
Receptors, Chemokine / biosynthesis
Receptors, Chemokine / genetics
Up-Regulation / genetics
Up-Regulation / immunology*
fas Receptor / biosynthesis*
fas Receptor / blood*
fas Receptor / genetics

Substances

CCR3 protein, human
CCR5 Receptor Antagonists
CXCR3 protein, human
FASLG protein, human
Fas Ligand Protein
Ligands
Membrane Glycoproteins
RNA, Messenger
Receptors, CCR3
Receptors, CCR5
Receptors, CXCR3
Receptors, Chemokine
fas Receptor